Lara D. Veeken · 2024 · 10 citations · 38 references
MedicineImmunologyOtolaryngologyAutoimmunityImmunotherapyRheumatologyChronic RhinosinusitisEosinophilic DisordersNasal PolyposisNasal PolypsChronic Rhinosinusitis Without Nasal PolypsComplete Response AssessmentDupilumab ResponseEosinophilic InfiltratesNasal CytologyNasal SymptomsPrednisone UseRemission Measurement
OBJECTIVES: Eosinophilic granulomatosis with polyangiitis (EGPA) is frequently associated with refractory chronic rhinosinusitis with nasal polyps (CRSwNP), despite current treatments. Dupilumab demonstrated efficacy in the treatment of severe and uncontrolled CRSwNP, with improvements in patient-reported outcome measures (PROMs) and in objective measurements. This study aims to evaluate efficacy and safety of dupilumab in refractory CRSwNP in EGPA patients. METHODS: A prospective observational study was conducted on EGPA patients treated with dupilumab between 2021 and 2023. Patients in a phase of prolonged remission of vasculitis manifestations but still experiencing active CRSwNP were included. Clinical, biological, and rhinologic evaluations were performed, alongside with PROMs and nasal cytology. Complete response was defined by BVAS = 0 and prednisone dose ≤4 mg/day, while partial response by BVAS = 0 and prednisone dose >4 mg/day. RESULTS: Nine EGPA patients were included. After 3 months, 55.6% achieved complete response, increasing to 83.3% at 12 months. Nasal symptoms and patient-reported outcomes improved significantly, with sustained efficacy over 12 months. An improvement in quality of life was also observed, with a significant reduction in the AAV-PRO score. Nasal cytology revealed reductions in eosinophils and neutrophils counts. Adverse events occurred in 44.4%, including hypereosinophilia in two cases, which led to dupilumab discontinuation. CONCLUSION: Dupilumab is an effective treatment option for severe and refractory ENT manifestations in EGPA, as it improves symptoms, reduces inflammation, and leads to better a quality of life. However, careful patient selection and monitoring are necessary to minimize adverse events and optimize outcomes.
38
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Mario Castro, Jonathan Corren, Ian Pavord et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text
Pharmacy, Immunology, Pharmacology +13
Claus Bachert, Joseph K. Han, Martin Desrosiers et al. · The Lancet · 2019 · 1.5K citations
Medicine, Immunology, Otolaryngology +10
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
Chetan Mukhtyar, R Lee, Denise Scott Brown et al. · Annals of the Rheumatic Diseases · 2008 · 1.2K citations
Medicine, Cancer Biology, Oncology +14
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe, Parameswaran Nair, Guy Brusselle et al. · New England Journal of Medicine · 2018 · 1.2K citations · Full text
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler, Praveen Akuthota, David Jayne et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text